用于癌症治疗的重组毒素
1Division of Cancer Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.
概括
再组合毒素通过专门准瘤细胞,提供了一种新的癌症治疗方法. 与传统化疗不同,这些毒素提供了独特的作用机制,避免了交叉抵抗,降低了二次癌症的风险.
科学领域:
- 生物技术是生物技术.
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 传统化疗面临着诸如交叉耐药性和二次恶性瘤等挑战.
- 再组合毒素为癌症治疗提供了一个替代的治疗策略.
研究的目的:
- 探索重组毒素作为一种新型癌症治疗的潜力.
- 突出重组毒素相对于传统化疗剂的优势.
主要方法:
- 重组毒素的发展,包括生长因子-毒素和抗体-毒素融合.
- 在瘤细胞上准特定的细胞表面受体和抗原.
主要成果:
- 重组毒素表现出与传统化疗不同的细胞杀死机制.
- 这些毒素是非变异性的,因此不会诱导二次恶性瘤.
- 在细菌中,可实现对同质蛋白质的经济高效量产.
结论:
- 重组毒素是一种有希望的,更安全的,可能更有效的癌症治疗方法.
- 增长因子-毒素和抗体-毒素融合之间的选择取决于特定的细胞标.
- 这种方法绕过了与传统化疗相关的交叉耐药性和基因毒性问题.
相关概念视频
Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...


